CO2022008690A2 - Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso - Google Patents

Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso

Info

Publication number
CO2022008690A2
CO2022008690A2 CONC2022/0008690A CO2022008690A CO2022008690A2 CO 2022008690 A2 CO2022008690 A2 CO 2022008690A2 CO 2022008690 A CO2022008690 A CO 2022008690A CO 2022008690 A2 CO2022008690 A2 CO 2022008690A2
Authority
CO
Colombia
Prior art keywords
compounds
delta
methods
heterocyclic compounds
desaturase inhibitors
Prior art date
Application number
CONC2022/0008690A
Other languages
English (en)
Inventor
Jennifer R Allen
Michela Beltrani
Matthew P Bourbeau
Teodora P Damyanova
Iain Lingard
Ana E Minatti
Paolo Vincetti
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CO2022008690A2 publication Critical patent/CO2022008690A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente divulgación proporciona compuestos útiles para la inhibición de Delta-5 Desaturasa (“D5D”). Los compuestos tienen una fórmula general I: I en la que las variables de Fórmula I se definen en la presente. Esta divulgación también proporciona composiciones farmacéuticas que comprenden los compuestos, usos de los compuestos y composiciones para el tratamiento de, por ejemplo, un trastorno metabólico o cardiovascular. Además, la divulgación proporciona productos intermedios útiles en la síntesis de compuestos de Fórmula I.
CONC2022/0008690A 2019-11-25 2022-06-22 Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso CO2022008690A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962939821P 2019-11-25 2019-11-25
PCT/US2020/062020 WO2021108408A1 (en) 2019-11-25 2020-11-24 Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use

Publications (1)

Publication Number Publication Date
CO2022008690A2 true CO2022008690A2 (es) 2022-06-30

Family

ID=73855555

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0008690A CO2022008690A2 (es) 2019-11-25 2022-06-22 Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso

Country Status (19)

Country Link
US (3) US11512097B2 (es)
EP (1) EP4065223A1 (es)
JP (2) JP7254246B2 (es)
KR (2) KR102598203B1 (es)
CN (2) CN118161500A (es)
AR (1) AR120556A1 (es)
AU (1) AU2020392087A1 (es)
BR (1) BR112022010054A2 (es)
CA (1) CA3162281A1 (es)
CL (2) CL2022001357A1 (es)
CO (1) CO2022008690A2 (es)
CR (1) CR20220308A (es)
IL (1) IL293191A (es)
JO (1) JOP20220125A1 (es)
MX (1) MX2022006281A (es)
PE (1) PE20231097A1 (es)
TW (2) TWI815061B (es)
UY (1) UY38971A (es)
WO (1) WO2021108408A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7254246B2 (ja) 2019-11-25 2023-04-07 アムジエン・インコーポレーテツド デルタ－５デサチュラーゼ阻害剤としての複素環式化合物及び使用方法
CN115557903A (zh) * 2022-09-27 2023-01-03 山东潍坊润丰化工股份有限公司 一种特草定的制备方法
WO2024112763A1 (en) 2022-11-23 2024-05-30 Amgen Inc. Selection of patients for the treatment of fads1-mediated diseases or disorders using fads-1 inhibitors

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3130633A1 (de) 1981-08-01 1983-02-17 Basf Ag, 6700 Ludwigshafen 7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide
DE3786365T2 (de) 1986-04-07 1993-10-21 Ihara Chemical Ind Co 5H-1,3,4-Thiadiazolo[3,2-a]pyrimidin-5-on-Derivate und diese enthaltende Gartenbau- und landwirtschaftliche Fungizidmittel.
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
EP0948496A2 (en) 1996-12-05 1999-10-13 Amgen inc. Substituted pyrimidinone and pyridone compounds and methods of use
EP1220857B1 (en) 1999-10-15 2005-09-21 Neurocrine Biosciences, Inc. Gonadotropin releasing hormone receptor antagonists and their related methods of use
US6537998B1 (en) * 1999-10-15 2003-03-25 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
TW200401770A (en) 2002-06-18 2004-02-01 Sankyo Co Fused-ring pyrimidin-4(3H)-one derivatives, processes for the preparation and uses thereof
JP2004107228A (ja) 2002-09-17 2004-04-08 Nippon Nohyaku Co Ltd 双環性ピリミジノン誘導体及びこれを有効成分とする除草剤
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
AR049769A1 (es) 2004-01-22 2006-09-06 Novartis Ag Derivados de pirazolo(1,5-a)pirimidin 7-il-amina para utilizarse en el tratamiento de enfermedades dependientes de la quinasa de proteina
CA2612585A1 (en) 2005-06-27 2007-01-04 Amgen Inc. Anti-inflammatory aryl nitrile compounds
EP1905238A4 (en) 2005-07-18 2009-04-22 Samsung Electronics Co Ltd VIDEO CODING METHOD AND DEVICE FOR INCREASING CONFORMITY BETWEEN ENCODERS AND DECODERS
AU2006274075A1 (en) 2005-07-27 2007-02-01 Basf Se Fungicide 6-phenyl-triazolopyrimidinyl amines
JP2009502863A (ja) 2005-07-27 2009-01-29 ビーエーエスエフ ソシエタス・ヨーロピア ６−フェニル−ピラゾロピリミジン−７−イルアミン殺菌剤
CN101227819A (zh) 2005-07-27 2008-07-23 巴斯福股份公司 杀真菌剂5-甲基-6-苯基三唑并嘧啶基胺
BRPI0616985B1 (pt) 2005-10-06 2021-10-26 Merck Sharp & Dohme Corp. Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto
JP2010504927A (ja) 2006-09-28 2010-02-18 ノバルティス アーゲー ピラゾロ［１，５−ａ］ピリミジン誘導体およびそれらの治療的使用
WO2008057601A2 (en) 2006-11-08 2008-05-15 The Rockefeller University Organic compounds
US20080194557A1 (en) 2007-01-18 2008-08-14 Joseph Barbosa Methods and compositions for the treatment of pain, inflammation and cancer
US20080200458A1 (en) 2007-01-18 2008-08-21 Joseph Barbosa Methods and compositions for the treatment of body composition disorders
NZ578205A (en) 2007-01-19 2010-11-26 Basf Se Fungicidal mixtures of 1-methylpyrazol-4-ylcarboxylic acid anilides and azolopyrimidinylamines
EP2131658A2 (en) 2007-01-30 2009-12-16 Basf Se Method for improving plant health
BRPI0809045A2 (pt) 2007-03-23 2014-09-02 Basf Se Combinações de substância ativa, uso de combinações de substância ativa, métodos para combater fungos fitopatogênicos indesejáveis, para preparar agentes pesticidas, e para tratar sementes, e, produto de revestimento de semente
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2274308A1 (en) * 2008-04-04 2011-01-19 Gilead Sciences, Inc. Pyrrolotriazinone derivatives for use as stearoyl coa desaturase inhibitors
US8119647B2 (en) * 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
UY32395A (es) 2009-01-27 2010-08-31 Takeda Pharmaceutical Compuesto con anillo fusionado y su uso
EP2845856A1 (en) 2009-06-29 2015-03-11 Incyte Corporation Pyrimidinones as PI3K inhibitors
WO2011114148A1 (en) 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
JPWO2012011592A1 (ja) 2010-07-23 2013-09-09 武田薬品工業株式会社 複素環化合物およびその用途
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US8952012B2 (en) 2012-05-24 2015-02-10 Colorado State University Research Foundation Inhibition of delta-6 desaturase for the treatment of cardiometabolic disease
US10035801B2 (en) 2013-03-13 2018-07-31 Genentech, Inc. Pyrazolo compounds and uses thereof
RU2016112568A (ru) 2013-09-05 2017-10-06 Дженентек, Инк. Антипролиферативные соединения
WO2015064714A1 (ja) 2013-10-31 2015-05-07 国立大学法人東京大学 オートタキシン阻害活性を有する１－置換イミダゾピリミジノン誘導体
WO2015135094A1 (en) 2014-03-13 2015-09-17 Genentech, Inc. Therapeutic compounds and uses thereof
BR112016024455B1 (pt) 2014-04-23 2023-02-07 Mitsubishi Tanabe Pharma Corporation Composto heterocíclico bicíclico ou tricíclico
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
JP6791717B2 (ja) 2015-10-22 2020-11-25 田辺三菱製薬株式会社 医薬組成物
WO2017112678A1 (en) 2015-12-21 2017-06-29 Rima Mcleod Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases
MX2019002303A (es) 2016-08-31 2019-07-15 Agios Pharmaceuticals Inc Inhibidores de procesos metabolicos celulares.
WO2018039972A1 (en) * 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
CN106749271B (zh) * 2016-12-07 2019-04-05 青岛科技大学 一类[1,2,4]-三氮唑并[1,5-a]嘧啶酮类杂环化合物、其制备方法及其用途
SG11201910197SA (en) 2017-05-15 2019-11-28 Dana Farber Cancer Inst Inc Compounds for treating dengue virus infection and other viral infections
WO2018229683A1 (en) 2017-06-15 2018-12-20 Novartis Ag 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
BR112020003676A2 (pt) 2017-09-15 2020-09-01 Aduro Biotech, Inc. compostos de pirazolopirimidinona e usos dos mesmos
JP7254246B2 (ja) 2019-11-25 2023-04-07 アムジエン・インコーポレーテツド デルタ－５デサチュラーゼ阻害剤としての複素環式化合物及び使用方法

Also Published As

Publication number Publication date
PE20231097A1 (es) 2023-07-18
CL2023002486A1 (es) 2024-01-12
US20210221824A1 (en) 2021-07-22
CN118161500A (zh) 2024-06-11
TW202409042A (zh) 2024-03-01
TWI815061B (zh) 2023-09-11
UY38971A (es) 2021-06-30
MX2022006281A (es) 2022-06-08
BR112022010054A2 (pt) 2022-08-16
CN114728167B (zh) 2024-03-19
KR20230154292A (ko) 2023-11-07
US11512097B2 (en) 2022-11-29
JP2023078418A (ja) 2023-06-06
CR20220308A (es) 2022-08-04
KR20220106159A (ko) 2022-07-28
US20230159560A1 (en) 2023-05-25
JP7254246B2 (ja) 2023-04-07
AU2020392087A1 (en) 2022-06-09
IL293191A (en) 2022-07-01
US20210188874A1 (en) 2021-06-24
WO2021108408A1 (en) 2021-06-03
KR102598203B1 (ko) 2023-11-03
TW202132317A (zh) 2021-09-01
CL2022001357A1 (es) 2023-03-10
AR120556A1 (es) 2022-02-23
CA3162281A1 (en) 2021-06-03
JOP20220125A1 (ar) 2023-01-30
CN114728167A (zh) 2022-07-08
JP2022549739A (ja) 2022-11-28
EP4065223A1 (en) 2022-10-05

Similar Documents

Publication Publication Date Title
CO2022008690A2 (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
CO2019007810A2 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
CL2017000469A1 (es) Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
CO6400220A2 (es) Derivados de sulfonamida
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
CO6290687A2 (es) Inhibidores de cinasa pim y metodos para su uso
ECSP11011113A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
ECSP11011412A (es) Atropisómeros de derivados de 2-purinil-3-tolil-quinazolinona y métodos de uso
CO6300939A2 (es) Compuestos novedosos que son inhibidores de erk referencia a una solicitud relacionada
ECSP109953A (es) Derivados de piridazinona
UY31906A (es) Derivados de n-cicloalquil-3-fenilnicotinamida que inhiben pgds, sus composiciones, su uso para el tratamiento por ejemplo de afecciones alérgicas y respiratorias.
CL2009000429A1 (es) Compuestos derivados de carbamoil-heterociclos fusionados, en especial pirrolo[3,2-c]piridin-2-carboxamidas, inhibidores de smo; composicion farmaceutica que comprende dichos compuestos; y uso en la profilaxis o tratamiento del cancer.
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
AR078613A1 (es) Derivados de sulfoxidos benzooxazolicos y benzotriazolicos inhibidores de autotaxinas, medicamentos que los contienen y uso de los mismos para el tratamiento de tumores.
BR112016028876A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos.
AR108461A1 (es) Compuestos imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
AR084216A1 (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
UY38972A (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
CO2022000266A2 (es) Inhibidores de enzimas
GT201100039A (es) Agentes antifúngicos
CR11860A (es) Derivados de dibenzotiazepina y sus usos - 424
AR077429A1 (es) Compuestos hidroxiasenapina sus derivados y composiciones farmaceuticas que comprenden los mismos
UY38133A (es) Nuevos inhibidores de cdk8/19